Michelle Lavin
Overview
Explore the profile of Michelle Lavin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
552
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Peterson W, Martin R, Arnold D, Carvalho B, Cuker A, Gadsden J, et al.
J Thromb Haemost
. 2025 Feb;
PMID: 39952359
Background: Neuraxial anaesthesia is used for pain management in surgical and non-surgical settings. Spinal/epidural haematomas likely occur in between 1:10,000 and 1:200,000 procedures. Risk is thought to be greater in...
2.
ODonnell M, Abdul Kadir R, van Galen K, Lavin M
Haemophilia
. 2025 Feb;
PMID: 39917900
No abstract available.
3.
Clearfield E, Kim B, Ford S, Connell N, Santaella M, Lavin M, et al.
Haemophilia
. 2024 Nov;
30(6):1357-1365.
PMID: 39604131
Introduction: Treatment options are expanding for von Willebrand disease (VWD). A core outcome set (COS)-a minimum set of agreed-upon outcomes to be used in every clinical trial for a given...
4.
Blatny J, Astermark J, Catarino C, Dolan G, Fijnvandraat K, Hermans C, et al.
Ther Adv Hematol
. 2024 Oct;
15:20406207241285143.
PMID: 39381602
Over recent decades, management of people with hemophilia (PwH) has been greatly improved by scientific advances that have resulted in a rich and varied therapeutic landscape. Nevertheless, treatment limitations continue...
5.
Kelly C, Thomas W, Baker R, ODonnell J, Sanchez-Luceros A, Lavin M
J Thromb Haemost
. 2024 Jun;
22(10):2900-2909.
PMID: 38866246
Background: Bleeding disorder of unknown cause (BDUC) is characterized by a bleeding phenotype in the setting of normal hemostatic testing. No standardized diagnostic criteria or treatment algorithms exist for people...
6.
Dolan G, Fijnvandraat K, Lenting P, Catarino C, Lavin M
Semin Thromb Hemost
. 2024 May;
51(1):58-67.
PMID: 38733982
People with nonsevere hemophilia (PWNSH) are phenotypically more diverse than those with severe hemophilia. Perceptions relating to a "nonsevere" phenotype have contributed to fewer research initiatives, fewer guidelines on optimal...
7.
Baker R, Choi P, Curry N, Gebhart J, Gomez K, Henskens Y, et al.
J Thromb Haemost
. 2024 Mar;
22(7):2059-2070.
PMID: 38518896
In many patients referred with significant bleeding phenotype, laboratory testing fails to define any hemostatic abnormalities. Clinical practice with respect to diagnosis and management of this patient cohort poses significant...
8.
Mahlangu J, Diop S, Lavin M
Haemophilia
. 2024 Mar;
30 Suppl 3:78-85.
PMID: 38462793
The 2022 World Federation of Haemophilia Annual Global Survey (AGS) reports that 454,690 patients with inherited bleeding disorders (IBD) have been identified globally. While this represents noteworthy progress, haemophilia epidemiology...
9.
Atiq F, Blok R, van Kwawegen C, Doherty D, Lavin M, van der Bom J, et al.
Blood
. 2023 Dec;
143(14):1414-1424.
PMID: 38142407
There is significant ongoing debate regarding type 1 von Willebrand disease (VWD) defintion. Previous guidelines recommended patients with von Willebrand factor (VWF) levels <30 IU/dL be diagnosed type 1 VWD,...
10.
Doherty D, Lavin M
Lancet Haematol
. 2023 Nov;
10(11):e875-e876.
PMID: 37914479
No abstract available.